Compile Data Set for Download or QSAR
Report error Found 23 Enz. Inhib. hit(s) with all data for entry = 11643
TargetIntegrin alpha-V/beta-1(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM636498(US20230365556, Compound 93)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-1(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM636507(US20230365556, Compound 122)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-1(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM636506(US20230365556, Compound 121)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-1(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM636505(US20230365556, Compound 119)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-1(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM636504(US20230365556, Compound 118)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-1(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM636503(US20230365556, Compound 117)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-1(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM636502(US20230365556, Compound 97)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-1(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM636501(US20230365556, Compound 96)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-1(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM636500(US20230365556, Compound 95)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-1(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM636499(US20230365556, Compound 94)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-1(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM636497(US20230365556, Compound 92)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-1(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM636496(US20230365556, Compound 91)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-1(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM636495(US20230365556, Compound 90)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-1(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM636494(US20230365556, Compound 89)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-1(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM636493(US20230365556, Compound 88)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-1(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM636491(US20230365556, Compound 87)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-1(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM636490(US20230365556, Compound 81 | 2-(1-methyl-1H-indazo...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-1(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM636488(US20230365556, Compound 65 | 2-(2,6-dichlorobenzam...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-1(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM636511(US20230365556, Compound 126)
Affinity DataIC50: 150nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-1(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM636489(US20230365556, Compound 75 | 2-(2,6-dichlorobenzam...)
Affinity DataIC50: 625nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-1(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM636508(US20230365556, Compound 123)
Affinity DataIC50: 1.00E+3nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-1(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM636509(US20230365556, Compound 124)
Affinity DataIC50: 1.00E+3nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-1(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM636510(US20230365556, Compound 125)
Affinity DataIC50: 1.00E+3nMAssay Description:Microplates were coated with recombinant human integrin αvβ1 (2 ug/ml) in PBS (100 ul/well 4° C., overnight). The coating solution was remo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent